Abacus Medicine Pharma Services (AMPS) and Laboratoires CTRS, marketing authorization holder of Orphacol®, are proud to announce a strategic partnership that ensures continuous stock of Orphacol® in Spain. Furthermore, the partnership means improved delivery lead times for customers as well as implementation of simplified sales, distribution, and administration processes for Laboratoires CTRS, thus saving individual deliveries and the associated administration.
Orphacol® is a medicine containing cholic acid, a substance found in the bile, which is used to digest fats.
It is used to treat adults and children from one month of age who have a genetic abnormality that makes them unable to produce bile. Orphacol is used in patients who do not have enough of two specific liver enzymes (3β-hydroxy-Δ5-C27-steroid oxidoreductase or Δ4-3-oxosteroid-5β-reductase). This makes their liver unable to produce enough of the main components of bile, called primary bile acids, such as cholic acid. When these primary bile acids are lacking, the body produces abnormal bile acids instead which can damage the liver, potentially leading to life-threatening liver failure.
Simon Estcourt, Managing Director of Abacus Medicine Pharma Services explains:
“I am very proud of the partnership agreement between Abacus Medicine Pharma Services and Laboratoires CTRS. Our ambition is to provide better access to medicines and better healthcare to patients around the world. This partnership with Laboratoires CTRS will ensure reliable availability to Orphacol ® in Spain at all times, as well as improved delivery time for customers.”
Franck Hamalian, President of Laboratoires CTRS states:
“With this partnership, CTRS and AMPS, reduce lead time for delivery and further enhance availability of Orphacol® for patients in need on the Spanish territory. We know this to be a factor of highest importance for the life-saving treatment that is Orphacol® and are glad to join forces with such a robust and growing actor as AMPS.”
3β-hydroxy-Δ5-C27-steroid oxidoreductase or Δ4-3-oxosteroid-5β-reductase deficiencies are part of are a group of Bile Acid Synthesis Disorders (BASD) which are rare metabolic diseases caused by a lack of various liver enzymes involved in the synthesis of bile acids. This makes the liver unable to produce enough of the main components of bile such as cholic acid. BASD are responsible for 1-2% of cases of neonatal cholestasis that occurs in approximately 1 in 2,500 births and is the main cause of liver-related paediatric hospitalisations as well as 80% of paediatric liver transplantations.
- Orphacol® film-coated tablets 30 pcs. 250mg (Código nacional: 7048480)
- Orphacol® film-coated tablets 30 pcs. 50mg (Código nacional: 7048756)
Abacus Medicine Pharma Services is part of the Abacus Medicine Group, a fast-growing supplier of original prescription medicines. +1,200 employees service thousands of customers in Europe and the rest of the world. With a customised ERP system, a bespoke global distribution centre and a leadership team with decades of experience, AMPS is evolving into the next-generation healthcare and pharma services company by combining the infrastructure and skills at Abacus Medicine with the experience and expertise within AMPS. For more information on Abacus Medicine Pharma Services, please go to https://abacusmedicinepharmaservices.com/.
Laboratoires CTRS is a French pharmaceutical company with a strong international presence, dedicated to rare and ultra-rare diseases. CTRS has successfully established both public and private partnerships and collaborations with major research groups that mainly focus on genetic diseases and cancer. The company has more than 20 collaborators as well as a network of long-standing commercial partners all over the world. For more information on CTRS, please go to http://www.ctrs.fr.
For communication queries regarding Abacus Medicine Pharma Services, please contact:
Andrew Waiton, Senior Marketing Consultant
Phone: +44 7810 265 076
For ordering queries, please contact:
For communication queries regarding Laboratoires CTRS, please contact:
Anne-Sophie Degorce-Dumas, Marketing and Market Access Director
Phone: +33 (01) 72 69 01 86